SecBot SecBot
PRESS-RELEASE ·Filed Jun 16, 2026

OTLK

Outlook Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The FDA Class 1 review with a 6-week PDUFA date (July 29) is a strong positive signal that the resubmission is complete and reviewable. Traders should watch for potential FDA decision by late July; a positive outcome could drive significant upside given the first-to-market positioning and existing EU/UK approvals. Monitor for any FDA briefing documents or AdCom announcements in the interim.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.57
T+0 close · Jun 16, 2026 · via day close
Latest settled
−57.89%
T+60 · $0.6612
Vs SPY
−58.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $1.57entry
  2. T+1 · 5mo ago +5.10%α +6.34% · $1.65
  3. T+5 · 5mo ago +8.28%α +10.51% · $1.70
  4. T+20 · 4mo ago +10.19%α +9.99% · $1.73
  5. T+60 · 2mo ago −57.89%α −58.88% · $0.6612
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD as a Class 1 review with a PDUFA target date of July 29, 2026. The company has initiated pre-launch activities, and approval would make it the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and labeling. This is a major regulatory milestone for a $162M market-cap biotech with a single primary asset.

Key Facts

  • FDA accepted resubmitted BLA for ONS-5010/LYTENAVA as Class 1 review
  • PDUFA target action date set for July 29, 2026
  • ONS-5010/LYTENAVA already has EU and UK marketing authorization for wet AMD
  • Company has initiated pre-launch activities in anticipation of potential approval
  • First and only FDA-approved ophthalmic formulation of bevacizumab would be a novel product

Financial Impact

Potential US market approval for first ophthalmic bevacizumab; no financial figures provided in release

revenuemarket accesscommercialization

Risk Factors

  • FDA may issue a Complete Response Letter (CRL) despite Class 1 acceptance
  • Manufacturing or labeling issues could delay or prevent approval
  • Competition from existing anti-VEGF therapies (e.g., Eylea, Lucentis, Vabysmo) may limit market share

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3312535

Track record

37 reports on OTLK

Performance horizon

12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026